You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2024

Concordia Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CONCORDIA, and what generic and branded alternatives to CONCORDIA drugs are available?

CONCORDIA has fifteen approved drugs.

Summary for Concordia

US Patents:	0
Tradenames:	16
Ingredients:	14
NDAs:	15

Drugs and US Patents for Concordia

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Concordia	LANOXIN	digoxin	TABLET;ORAL	020405-006	Sep 30, 1997		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Concordia	NILANDRON	nilutamide	TABLET;ORAL	020169-002	Apr 30, 1999	AB	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Concordia Pharms Inc	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-001	Jun 1, 2006		RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Concordia	DUTOPROL	hydrochlorothiazide; metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	021956-002	Aug 28, 2006		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Concordia

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Concordia Pharms Inc	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-001	Jun 1, 2006	5,178,878	⤷ Subscribe
Concordia Pharms Inc	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-002	Jun 1, 2006	6,740,341	⤷ Subscribe
Concordia Pharms Inc	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-002	Jun 1, 2006	5,178,878	⤷ Subscribe
Concordia	UROXATRAL	alfuzosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021287-001	Jun 12, 2003	6,149,940*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for CONCORDIA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	10 mg	➤ Subscribe	2007-06-12
➤ Subscribe	Extended-release Tablets	0.1 mg and 0.2 mg	➤ Subscribe	2011-03-04
➤ Subscribe	Orally Disintegrating Tablets	10 mg, 15 mg and 30 mg	➤ Subscribe	2010-07-22
➤ Subscribe	Extended-release Tablets	0.1 mg and 0.2 mg	➤ Subscribe	2011-03-04

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.